ClinicalTrials.gg
CompletedNCT02693119Updated Nov 30, 2021Results posted

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

A Phase 2 interventional study of elamipretide (MTP-131) 1% topical ophthalmic solution and Vehicle topical ophthalmic solution in Leber's Hereditary Optic Neuropathy, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-11-30.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States — 4 open to participants now, 6 under way, 2 of them phase 3. Optic Atrophy, Hereditary, Leber · United States.

Enrollment
14th of 19
12 · median 36
Started
2016
with 5 others
Phase 2
3 of 23
none open now
Registered
10th of 23
by date

Among the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2016, is one of 3 in phase 2, and was the 10th registered.

Optic Atrophy, Hereditary, Leber

44 studies on the registry are indexed under Optic Atrophy, Hereditary, Leber; 9 are open to participants now.

Browse Optic Atrophy, Hereditary, Leber studies →

Open to participants now

4 of the 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Optic Atrophy, Hereditary, Leber studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Optic Atrophy, Hereditary, Leber with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, prospective, randomized, double-masked, vehicle controlled, single-center study in approximately 12 subjects with LHON to evaluate safety, tolerability and efficacy of elamipretide (MTP-131) topical ophthalmic solution in this patient population. At the conclusion of 52 weeks of treatment, subjects will be offered the opportunity to enter an Open Label Extension for up to 48 additional weeks of treatment.

Read the detailed description

This was a prospective, randomized, double-masked (DM), vehicle-controlled, single-center study plus open label extension period (OLE) in which approximately 12 subjects with LHON having the genetic mtDNA mutation m.11778G>A were randomized in a masked manner into 1 of 3 groups in a 1:1:1 ratio: one drop of elamipretide 1.0% topical ophthalmic solution twice daily (BID) in the: left eye, right eye, or both eyes.

After completion of the 52-week treatment period or the Week 56 follow-up period, subjects were invited to participate in the OLE period for up to 108 weeks. During the OLE participants received 1% topical opthalmic elamipretide in both eyes (OU) daily. If a subject did not consent to the OLE, he/she completed the study at the Week 56 (±7 days) visit. There were 4 periods in this study: (1) screening period (up to 6 weeks); (2) double-masked treatment period (52 weeks); (3) OLE period (up to 108 weeks), and (4) follow-up period (4 weeks) after completion of End-of-Treatment (EOT) visit.

03

Conditions studied

  • Leber's Hereditary Optic Neuropathy

Keywords

  • LHON
  • Ocuvia™
  • elamipretide
  • MTP-131
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 and ≤ 50 years old at the time of loss of vision in the second eye.
  • Able to provide and willing to comply with all study visits and examinations
  • Diagnosis of LHON based on clinical and ophthalmic functional/anatomic test findings, and satisfactory documentation of the mitochondrial DNA mutation m.11778G>A
  • Loss of vision in both eyes of ≥1 year and ≤10 years at the time of the Screening Visit and current clinically stable visual function (as assessed by the Investigator)
  • Able to self-administer eye drops as demonstrated at screening or having a care provider who can do so
  • Documentation of having satisfactorily completed at least two previous Humphrey automated visual field tests prior to screening.
  • Women of must agree to use as specified in the protocol from the date they sign the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Any other ocular pathology requiring treatment with prescription topical ophthalmic drops (e.g., glaucoma, dry eye)
  • Cup to disc ratio of > 0.8 in either eye
  • Media opacity, suboptimal pupillary dilatation, or refractive error that interferes with adequate retinal imaging
  • Known to be or receiving systemic immunosuppression
  • Any disease or medical condition that in the opinion of the Investigator would prevent the subject from participating in the study or might confound study results
  • Participation in other drug or device clinical trials within 30 days prior to enrollment, or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion
  • Women who are pregnant or lactating

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Group 1

    One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution BID in the fellow eye

    Drug: elamipretide (MTP-131) 1% topical ophthalmic solution · Drug: Vehicle topical ophthalmic solution

  • Experimental
    Group 2

    One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution BID in the fellow eye

    Drug: elamipretide (MTP-131) 1% topical ophthalmic solution · Drug: Vehicle topical ophthalmic solution

  • Experimental
    Group 3

    One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).

    Drug: elamipretide (MTP-131) 1% topical ophthalmic solution

  • Experimental
    OLE

    One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).

    Drug: elamipretide (MTP-131) 1% topical ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Double Masked Period: Incidence of Ocular TEAEs

    The incidence of ocular treatment emergent adverse events (TEAEs).

    Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)

  2. Open Label Extension: Incidence of Ocular TEAEs

    Open Label Extension: The incidence of ocular treatment emergent adverse events (TEAEs).

    Time frame: Assessed at Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)

  3. Double Masked Period: Severity of Ocular TEAEs

    The severity of ocular treatment emergent adverse events (TEAEs).

    Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)

  4. OLE: Severity of Ocular TEAEs

    The severity of ocular treatment emergent adverse events (TEAEs).

    Time frame: Assessed at Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)

  5. Double Masked Period: Best Corrected Visual Acuity (BCVA)

    Double Masked Period: Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

    Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)

  6. Open Label Extension Period: Best Corrected Visual Acuity (BCVA) Using the Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale

    Open Label Extension Period: Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160 (follow-up visit).

Secondary outcomes

  1. Double Masked Period: Photopic Negative Response Electroretinography (PhNR-ERG) A-wave Amplitude

    Change from baseline in photopic negative response electroretinography (PhNR-ERG) a-wave amplitude by Visit. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. Change from baseline in a-wave amplitude: a more positive number equals a decrease in amplitude, and therefore a worse outcome, a more negative number mean a better outcome.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.

  2. Open Label Extension Period: Photopic Negative Response Electroretinography (PhNR-ERG) A-wave Amplitude

    Change from baseline in photopic negative response electroretinography (PhNR-ERG) a-wave Amplitude by Visit. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. Change from baseline in a-wave amplitude: a more positive number equals a decrease in amplitude, and therefore a worse outcome, a more negative number mean a better outcome.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  3. Double Masked Period: Photopic Negative Response Electroretinography (PhNR-ERG) B-wave Amplitude

    Change from baseline in photopic negative response electroretinography (PhNR-ERG) b-wave amplitude by visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in the amplitude of the b-wave is associated with worse outcomes. Change from baseline in b-wave amplitude: a more negative number equals a decrease in amplitude, and therefore a worse outcome, a more positive number mean a better outcome.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.

  4. Open Label Extension Period: PhNR-ERG B-wave Amplitude

    Change from baseline in photopic negative response electroretinography (PhNR-ERG) b-wave Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in the amplitude of the b-wave is associated with worse outcomes. Change from baseline in b-wave amplitude: a more negative number equals a decrease in amplitude, and therefore a worse outcome, a more positive number means a better outcome.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  5. Double Masked Period: PhNR Amplitude

    Double Masked Period: Change from baseline in PhNR Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in PhNR amplitude means worse outcome. Change from baseline: A more negative number means a better outcome, a more positive number means a worse outcome.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.

  6. Open Label Extension Period: PhNR Amplitude

    Open Label Extension Period: Change from baseline in PhNR Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in PhNR amplitude means worse outcome. Change from baseline: A more negative number means a better outcome, a more positive number means a worse outcome.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  7. Double Masked Period: PhNR/B-wave Amplitude Ratio

    Double Masked Period: Change from baseline in PhNR/b-wave amplitude ratio by Visit. Photopic negative response electroretinography (PhNR assesses retinal cell function. A decrease in PhNR amplitude means worse outcome.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.

  8. Open Label Extension Period: Change From Baseline by Visit PhNR/b Wave Amplitude Ratio

    Open Label Extension Period: Change from baseline by visit PhNR/b Wave Amplitude Ratio by visit. A reduced amplitude ratio equals worse outcome.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  9. Double Masked Period: Change From Baseline by Visit PhNR Peak to Trough Adjusted for A-wave Amplitude

    Double Masked Period: Change from baseline by visit in PhNR Peak to Trough Adjusted for a-wave Amplitude by Visit. Calculated as (b-wave amplitude - PhNR amplitude)/a-wave amplitude. A reduced amplitude ratio equals worse outcome.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.

  10. Open Label Extension Period: Change From Baseline by Visit PhNR Peak to Trough Adjusted for A-wave Amplitude

    Open Label Extension Period: Change from baseline by visit in PhNR Peak to Trough Adjusted for a-wave Amplitude by Visit. \[Calculated by b-wave amplitude - PhNR amplitude)/a-wave amplitude.\] Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. A reduced amplitude ratio equals worse outcome.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  11. Double Masked Period: PhNR Peak to Trough Amplitude (Unadjusted) From Baseline

    Double Masked Period: Change from baseline in PhNR Peak to Trough Amplitude (Unadjusted) by Visit. Calculated as b-wave amplitude - PhNR amplitude. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in amplitude is associated with worse outcomes.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.

  12. Open Label Extension Period: PhNR Peak to Trough Amplitude (Unadjusted)

    Open Label Extension Period: Change from baseline in PhNR Peak to Trough Amplitude (Unadjusted) by Visit. b-wave amplitude - PhNR amplitude. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  13. Double Masked: VFQ-39 Composite

    Double Masked: Change from baseline in Visual Function Questionnaire (VFQ-39) Composite score by visit. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  14. Open Label Extension Period: VFQ-39 Composite Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Composite score.National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  15. Open Label Extension Period: VFQ-39 General Health Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) General Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  16. Double Masked: VFQ-39 General Vision Score

    Change from baseline in VFQ-39 General Vision Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculate

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  17. Open Label Extension Period: VFQ-39 General Vision Score

    Change from baseline in VFQ-39 General Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculate

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  18. Double Masked: VFQ-39 Ocular Pain Score

    Change from baseline in VFQ-39 Ocular Pain score. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  19. Open Label Extension Period: VFQ-39 Ocular Pain Score

    Change from baseline in VFQ-39 Ocular Pain score by visit. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  20. Double Masked: VFQ-39 Near Activities Score

    Change from Baseline in VFQ-39 Near Activities Score from Baseline. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  21. Open Label Extension Period: VFQ-39 Near Activities

    Change from Baseline in Visual Function Questionnaire (VFQ-39) Near Activities score.. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; score ranges from 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  22. Double Masked Period: Mean Retinal Nerve Fiber (RNFL) Layer Thickness

    Change from baseline in retinal nerve fiber layer thickness by spectral domain optical coherence tomography (SD-OCT). RNFL measures the loss of retinal ganglion cell axons. RNFL thickness decreases as disease progresses. A positive number, or, absence of change from baseline reflects a good clinical outcome, a negative number reflects loss of thickness, or a bad outcome.

    Time frame: Assessed at Baseline and Week 52 (end-of-treatment visit)

  23. Open Label Extension Period: Retinal Nerve Fiber Layer Thickness

    Open Label Extension Period: Change from baseline in Retinal Nerve Fiber Layer Thickness by SD-OCT by visit. Change from baseline in retinal nerve fiber layer thickness by spectral domain optical coherence tomography (SD-OCT). RNFL measures the loss of retinal ganglion cell axons. RNFL thickness decreases as disease progresses. A positive number, or, absence of change from baseline reflects a good clinical outcome, a negative number reflects loss of thickness, or a bad outcome.

    Time frame: Assessed at Baseline, Week 148

  24. Double Masked Period: Visual Field Mean Deviation as Measured by Humphrey Automated Visual Field Testing Stimulus III

    Change from Baseline in visual field Mean Deviation(MD) as measured by Humphrey automated visual field testing stimulus III by visit. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. Mean deviation (MD) is the mean deviation in the patient's results compared to those expected from the age-matched normative database. Lower/More negative scores mean worse outcome, higher/more positive score means better outcome.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.

  25. Open Label Extension Period: Visual Field Mean Deviation (dB) Measured by Humphrey From Baseline

    Change from Baseline in visual field Mean Deviation(MD) as measured by Humphrey automated visual field testing stimulus III by visit. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. Mean deviation (MD) is the mean deviation in the patient's results compared to those expected from the age-matched normative database. Lower/More negative scores mean worse outcome, higher/more positive score means better outcome.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  26. Double Masked Period: Color Discrimination - Number of Plates

    Double Masked Period: Change from Baseline in Color Discrimination - Number of Plates from Baseline by Visit by Ishihara Test. Score range: 0-38. Higher number equals better color discrimination equals better outcome. Lower number equals worse color discrimination equals worse outcome.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit)

  27. Open Label Extension Period: Change From Baseline in Color Discrimination - Number of Plates by Visit

    Open Label Extension Period: Change from Baseline in Color Discrimination - Number of Plates from Baseline by Visit by Ishihara Test. Score range: 0-38. Higher number equals better color discrimination equals better outcome. Lower number equals worse color discrimination equals worse outcome.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  28. Double Masked Period: Change From Baseline in Contrast Sensitivity by Pelli-Robson Contrast Sensitivity Chart by Visit

    Letters are arranged on a 60 x 85 cm chart in sets of triplets which contain the same contrast, decreasing in log10 contrast from top to bottom and left to right as participant progresses from one triplet to the other. Each group of three letters is decreased in contrast by a factor 0.71 (1/√2) (log contrast 0.15) of the proceeding set. Participant reads letters, starting with highest contrast, until unable to read letters in a single group. Score is based on the contrast of the last group read correctly.The size of the letters on the chart subtend 0.5 degrees at 3m, The test is scored in LogCS units, where each set of triplets advances in steps of 0.15 log units ranging from LogCS of 0.00 (approx. 100% contrast) to LogCS 2.25 (approx. 0.56% contrast). Change from baseline: the more negative the number means poor outcome, the more positive the number means better outcome.

    Time frame: Assessed at each visit from Baseline to Week 56 (follow-up visit)

  29. Open Label Extension Period: Change From Baseline in Contrast Sensitivity by Visit

    Letters are arranged on a 60 x 85 cm chart in sets of triplets which contain the same contrast, decreasing in log10 contrast from top to bottom and left to right as participant progresses from one triplet to the other. Each group of three letters is decreased in contrast by a factor 0.71 (1/√2) (log contrast 0.15) of the proceeding set. Participant reads letters, starting with highest contrast, until unable to read letters in a single group. Score is based on the contrast of the last group read correctly. The size of the letters on the chart subtend 0.5 degrees at 3m, The test is scored in LogCS units, where each set of triplets advances in steps of 0.15 log units ranging from LogCS of 0.00 (approx. 100% contrast) to LogCS 2.25 (approx. 0.56% contrast). Change from baseline: the more negative the number means poor outcome, the more positive the number means better outcome.

    Time frame: Assessed at each visit from Baseline from Week 68 to Week 160

  30. Double Masked Change From Baseline in Retinal Ganglion Cell Layer Thickness

    Change from baseline in Retinal Ganglion Cell Layer Thickness by SD-OCT From Baseline by Visit

    Time frame: Assessed at Baseline and Week 52 (end-of-treatment visit)

  31. Open Label Extension Period: Change From Baseline in Retinal Ganglion Cell Layer Thickness

    Open Label Extension Period: Change from baseline in Retinal Ganglion Cell Layer Thickness by SD-OCT by SD-OCT by visit

    Time frame: Assessed at Baseline, Week 148,

  32. Double Masked: VFQ-39 Distance Activities Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Distance Activities score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  33. Open Label Extension Period: VFQ-39 Distance Activities Score

    Change in Visual Function Questionnaire (VFQ-39) Distance Activities Score.National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  34. Open Label Extension Period: VFQ-39 Social Functioning Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Social Functioning Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  35. Double Masked: VFQ-39 Social Functioning Score.

    Change from baseline in Visual Function Questionnaire (VFQ-39) Social Functioning score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  36. Double Masked: VFQ-39 Mental Health Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Mental Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  37. Open Label Extension Period: VFQ-39 Mental Health Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Mental Health Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  38. Double Masked: VFQ-39 Role Difficulties Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Role Difficulties score National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  39. Open Label Extension Period: VFQ-39 Role Difficulties Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Role Difficulties Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  40. Open Label Extension Period:VFQ-39 Dependency Score

    Change from baseline in Visual Function Questionnaire (VFQ-39 ) Dependency Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  41. Double Masked: VFQ-39 Dependency Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Dependency score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  42. Double Masked: VFQ-39 Color Vision Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Color Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  43. Open Label Extension Period: VFQ-39 Color Vision Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Color Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  44. Double Masked: VFQ-39 Peripheral Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Peripheral Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

  45. Open Label Extension Period: Visual Function Questionnaire (VFQ-39) Peripheral Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) Peripheral Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 160 (End of OLE Period)

  46. Double Masked Period: Change in Intraocular Pressure (IOP)

    Double Masked Period: Change in intraocular Pressure (IOP) in mmHg from Baseline by Visit

    Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)

  47. Open Label Extension Period: Intraocular Pressure (IOP)

    Change from baseline in Intraocular Pressure (IOP) in mmHg by Visit.

    Time frame: Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)

  48. OLE: Slit Lamp Examination (SLE)-Vehicle Eye

    Open Label Extension: Shift in Slit Lamp Examination from Baseline by Visit: number of eyes that changed from normal or abnormal not clinically significant, to abnormal clinically significant for Vehicle Eyes

    Time frame: Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)

  49. OLE: Slit Lamp Examination (SLE)-Elamipretide Eye

    Open Label Extension: Shift in Slit Lamp Examination from Baseline by Visit: number of eyes that changed from normal or abnormal not clinically significant, to abnormal clinically significant for Elamipretide Eyes

    Time frame: Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)

  50. Double Masked: Slit Lamp Changes From Baseline: Vehicle Eye and Elamipretide Eye

    Incidence of Change from normal or Abnormal, clinically insignificant to normal clinically significant

    Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)

  51. Double Masked: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes

    Double Masked: Dilated Fundus Changes from Baseline: Vehicle Eye and Elamipretide Eyes Incidence of Change from normal or Abnormal-clinically insignificant, to normal clinically significant

    Time frame: Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)

  52. Open Label Extension Period: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes

    Incidence of Change from normal or Abnormal-clinically insignificant, to normal clinically significant

    Time frame: Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)

  53. Double Masked: VFQ-39 General Health Score

    Change from baseline in Visual Function Questionnaire (VFQ-39) General Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

    Time frame: Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)

07

Results

Posted Oct 12, 2021

Participant flow

Double-Blind Period
Participant flow — Double-Blind Period
MilestoneGroup 2Group 3
Started84
Completed84
Not completed00
Open-Label Period
Participant flow — Open-Label Period
MilestoneGroup 2Group 3
Started84
Completed83
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryDouble Masked Period: Incidence of Ocular TEAEs

The incidence of ocular treatment emergent adverse events (TEAEs).

Time frame:
Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Reported as:
Number · eyes
Double Masked Period: Incidence of Ocular TEAEs
eyesDouble Masked Group Vehicle EyesDouble Masked Group Elamipretide Eyes
Conjunctival hyperaemia38
Punctate keratitis13
Dry eye03
Eye irritation12
Eyelid irritation12
Eyelid exfoliation11
Lacrimation increased02
Choroidal neovascularisation01
Conjunctival oedema01
Eyelid oedema01
Noninfective conjunctivitis01
Immune system disorders: Hypersensitivity11
Infections and infestations Conjunctivitis11
Injury, poisoning and procedural complications: Foreign body in eye01
Injury, poisoning and procedural complications: Skin abrasion01
Investigations: Intraocular pressure increased11
Nervous system disorders: Parosmia02
PrimaryOpen Label Extension: Incidence of Ocular TEAEs

Open Label Extension: The incidence of ocular treatment emergent adverse events (TEAEs).

Time frame:
Assessed at Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Reported as:
Number · eyes
Open Label Extension: Incidence of Ocular TEAEs
eyesDouble Masked Group Vehicle EyesDouble Masked Group Elamipretide Eyes
Eye disorders Cataract nuclear11
Eye disorders Ocular hyperaemia11
Eye disorders Dry eye11
Eye disorders Eye irritation21
Eye disorders Eyelid irritation11
Eye disorders Visual acuity reduced11
Eye disorders Visual impairment02
Eye disorders Punctate keratitis10
General disorders and administration site conditions Application site pain (eyes burn, vision worse)35
Immune system disorders Seasonal allergy (worsening vision in eyes)11
Injury, poisoning and procedural complications: Corneal abrasian10
Injury, poisoning and procedural complications: Eye contusion01
Injury, poisoning and procedural complications: Fall (resulting in black eye)01
PrimaryDouble Masked Period: Severity of Ocular TEAEs

The severity of ocular treatment emergent adverse events (TEAEs).

Time frame:
Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Reported as:
Number · eyes
Double Masked Period: Severity of Ocular TEAEs
eyesVehicle Eyes: MildVehicle Eyes: ModerateVehicle Eyes: SevereElamipretide Eyes: MildElamipretide Eyes: ModerateElamipretide Eyes: Severe
Conjunctival hyperaemia200110
Punctate keratitis100300
Dry eye000300
Eye irritation100200
Eyelid irritation100200
Eyelid exfoliation100100
Lacrimation increased000200
Choroidal neovascularisation200001
Conjunctival oedema000100
Eyelid oedema000100
Noninfective conjunctivitis000010
Immune system disorders: Hypersensitivity100100
Infections and infestations Conjunctivitis010010
Injury, poisoning and procedural complications: Foreign body in eye000100
Injury, poisoning and procedural complications: Skin abrasion000100
Investigations: Intraocular pressure increased010010
Nervous system disorders: Parosmia000200
PrimaryOLE: Severity of Ocular TEAEs

The severity of ocular treatment emergent adverse events (TEAEs).

Time frame:
Assessed at Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Reported as:
Number · eyes
OLE: Severity of Ocular TEAEs
eyesVehicle to Elamipretide Eyes: MildVehicle to Elamipretide Eyes: ModerateVehicle to Elamipretide Eyes: SevereElamipretide to Elamipretide Eyes: MildElamipretide to Elamipretide Eyes: ModerateElamipretide to Elamipretide Eyes: Severe
Eye disorders Cataract nuclear500600
Punctate keratitis100000
Dry eye100100
Eye irritation200100
Eyelid irritation100100
Ocular hyperaemia100100
Visual acuity reduced100100
Visual impairment000200
General disorders and administration site conditions Application site pain300500
Immune system disorders Seasonal allergy100100
Injury, poisoning and procedural complications Corneal abrasian100000
Injury, poisoning and procedural complications Eye contusion000100
Injury, poisoning and procedural complications: Fall000100
PrimaryDouble Masked Period: Best Corrected Visual Acuity (BCVA)

Double Masked Period: Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

Time frame:
Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Reported as:
Mean · letters
Double Masked Period: Best Corrected Visual Acuity (BCVA)
lettersDouble Masked Group Vehicle EyesDouble Masked Group Elamipretide Eyes
Day 5-3.1 ± 9.34-0.5 ± 4.50
Week 40.3 ± 3.331.0 ± 3.54
Week 82.0 ± 3.020.5 ± 5.29
Week 122.8 ± 5.150.4 ± 6.47
Week 163.0 ± 3.380.6 ± 4.06
Week 204.0 ± 10.421.7 ± 4.63
Week 244.1 ± 9.982.1 ± 3.79
Week 285.5 ± 11.991.4 ± 4.99
Week 324.8 ± 15.542.7 ± 7.67
Week 366.6 ± 11.731.9 ± 4.53
Week 402.6 ± 11.563.2 ± 4.40
Week 446.1 ± 11.853.5 ± 5.97
Week 485.1 ± 16.584.8 ± 4.89
Week 524.6 ± 16.272.9 ± 5.45
Week 56 (follow up Visit)1.7 ± 2.895.3 ± 4.16
PrimaryOpen Label Extension Period: Best Corrected Visual Acuity (BCVA) Using the Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale

Open Label Extension Period: Best corrected visual acuity (BCVA) using the using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale by visit. ETDRS charts present a series of five letters of equal difficulty on each row, with standardized spacing between letters and rows; there is a total of 14 lines (70 letters), with letter size increasing further geometrically and equivalently in every line by a factor of 1.2589 (or 0.1 log unit), moving up the chart. Minimum score of zero, maximum score of 100. Change from baseline: a more negative score is worse outcome, a more positive score is better outcome. A lower score means less letters were read correctly (worse outcome) and a higher score means more letters were read correctly (better outcome).

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160 (follow-up visit).
Reported as:
Mean · letters
Open Label Extension Period: Best Corrected Visual Acuity (BCVA) Using the Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale
lettersVehicle to ElamipretideElamipretide to Elamipretide
Week 688.5 ± 14.166.00 ± 7.18
Week 8410.6 ± 18.665.4 ± 7.70
Week 1006.1 ± 13.866.1 ± 6.12
Week 104-3.5 ± 6.362.5 ± 0.71
Week 11611.3 ± 14.005.9 ± 6.71
Week 13211.6 ± 17.044.3 ± 8.36
Week 1482.8 ± 2.502.9 ± 4.05
Week 1601.7 ± 2.087.7 ± 4.16
SecondaryDouble Masked Period: Photopic Negative Response Electroretinography (PhNR-ERG) A-wave Amplitude

Change from baseline in photopic negative response electroretinography (PhNR-ERG) a-wave amplitude by Visit. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. Change from baseline in a-wave amplitude: a more positive number equals a decrease in amplitude, and therefore a worse outcome, a more negative number mean a better outcome.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Reported as:
Mean · µV
Double Masked Period: Photopic Negative Response Electroretinography (PhNR-ERG) A-wave Amplitude
µVVehicle EyesElamipretide Eyes
Week 40.0 ± 6.611.3 ± 6.81
Week 8-0.2 ± 6.920.5 ± 7.50
Week 12-3.5 ± 11.09-3.2 ± 10.18
Week 161.1 ± 6.710.7 ± 6.30
Week 201.5 ± 4.641.1 ± 4.71
Week 242.0 ± 6.182.0 ± 6.56
Week 280.4 ± 5.112.5 ± 5.80
Week 322.0 ± 8.180.3 ± 5.64
Week 36-2.5 ± 11.620.2 ± 7.00
Week 402.2 ± 10.071.5 ± 6.28
Week 441.0 ± 11.053.2 ± 6.55
Week 483.4 ± 8.312.9 ± 6.19
Week 522.3 ± 5.582.0 ± 5.16
Week 56 (Follow up Visit)7.0 ± 2.935.1 ± 8.71
SecondaryOpen Label Extension Period: Photopic Negative Response Electroretinography (PhNR-ERG) A-wave Amplitude

Change from baseline in photopic negative response electroretinography (PhNR-ERG) a-wave Amplitude by Visit. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. Change from baseline in a-wave amplitude: a more positive number equals a decrease in amplitude, and therefore a worse outcome, a more negative number mean a better outcome.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · µV
Open Label Extension Period: Photopic Negative Response Electroretinography (PhNR-ERG) A-wave Amplitude
µVVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 683.2 ± 9.244.0 ± 6.00
Week 84-7.1 ± 19.271.8 ± 6.81
Week 1008.0 ± 5.694.9 ± 4.41
Week 1045.3 ± 3.273.0 ± 1.71
Week 116-2.7 ± 9.390.3 ± 5.93
Week 1325.7 ± 7.071.4 ± 3.99
Week 1485.4 ± 8.921.5 ± 3.84
Week 1602.9 ± 2.822.82 ± 7.60
SecondaryDouble Masked Period: Photopic Negative Response Electroretinography (PhNR-ERG) B-wave Amplitude

Change from baseline in photopic negative response electroretinography (PhNR-ERG) b-wave amplitude by visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in the amplitude of the b-wave is associated with worse outcomes. Change from baseline in b-wave amplitude: a more negative number equals a decrease in amplitude, and therefore a worse outcome, a more positive number mean a better outcome.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Reported as:
Mean · µV
Double Masked Period: Photopic Negative Response Electroretinography (PhNR-ERG) B-wave Amplitude
µVVehicle EyesElamipretide Eyes
Week 4-9.1 ± 14.36-4.5 ± 31.48
Week 8-4.6 ± 21.82-3.4 ± 22.33
Week 123.5 ± 17.8514.6 ± 27.23
Week 16-2.8 ± 28.02-2.6 ± 19.83
Week 20-2.2 ± 22.48-6.4 ± 29.35
Week 24-8.9 ± 20.58-1.0 ± 28.06
Week 28-0.7 ± 19.04-11.6 ± 17.75
Week 32-5.6 ± 13.571.8 ± 24.58
Week 362.4 ± 29.872.2 ± 22.06
Week 40-0.1 ± 23.58-8.1 ± 23.17
Week 441.9 ± 21.35-5.0 ± 21.01
Week 48-6.9 ± 24.08-10.5 ± 23.80
Week 52-1.3 ± 13.97-5.4 ± 18.99
Week 56 (Follow up)-18.4 ± 28.05-17.5 ± 49.57
SecondaryOpen Label Extension Period: PhNR-ERG B-wave Amplitude

Change from baseline in photopic negative response electroretinography (PhNR-ERG) b-wave Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in the amplitude of the b-wave is associated with worse outcomes. Change from baseline in b-wave amplitude: a more negative number equals a decrease in amplitude, and therefore a worse outcome, a more positive number means a better outcome.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · µV
Open Label Extension Period: PhNR-ERG B-wave Amplitude
µVVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 68-15.4 ± 25.98-7.4 ± 17.10
Week 84-6.0 ± 23.97-13.1 ± 20.97
Week 100-28.7 ± 23.23-19.9 ± 18.04
Week 104-17.7 ± 5.23-14.2 ± 4.62
Week 11617.1 ± 44.404.9 ± 18.79
Week 132-17.1 ± 17.08-1.3 ± 18.81
Week 148-13.1 ± 30.88-7.3 ± 18.84
Week 160-17.8 ± 14.15-38.1 ± 25.20
SecondaryDouble Masked Period: PhNR Amplitude

Double Masked Period: Change from baseline in PhNR Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in PhNR amplitude means worse outcome. Change from baseline: A more negative number means a better outcome, a more positive number means a worse outcome.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Reported as:
Mean · µV
Double Masked Period: PhNR Amplitude
µVVehicle EyesElamipretide Eyes
Week 4-6.4 ± 22.270.3 ± 22.05
Week 8-4.6 ± 26.80-3.3 ± 27.28
Week 12-11.6 ± 26.59-0.7 ± 14.90
Week 16-4.5 ± 10.26-3.1 ± 17.35
Week 200.5 ± 20.65-3.1 ± 19.58
Week 24-4.3 ± 21.51-0.5 ± 16.15
Week 28-7.1 ± 26.32-1.5 ± 13.92
Week 32-4.1 ± 25.11-3.1 ± 13.61
Week 36-8.5 ± 24.94-3.4 ± 10.17
Week 40-2.3 ± 23.16-4.4 ± 10.92
Week 44-9.8 ± 29.75-1.5 ± 11.91
Week 48-2.8 ± 22.76-3.7 ± 13.14
Week 52-4.0 ± 25.41-3.3 ± 11.73
Week 56 (Follow up)-1.6 ± 16.71-5.7 ± 6.45
SecondaryOpen Label Extension Period: PhNR Amplitude

Open Label Extension Period: Change from baseline in PhNR Amplitude by Visit. Photopic negative response electroretinography (PhNR -ERG) assesses retinal cell function. A decrease in PhNR amplitude means worse outcome. Change from baseline: A more negative number means a better outcome, a more positive number means a worse outcome.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · µV
Open Label Extension Period: PhNR Amplitude
µVVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 68-7.1 ± 22.910.5 ± 16.60
Week 84-2.5 ± 25.45-2.2 ± 11.96
Week 1003.3 ± 16.251.8 ± 6.50
Week 1043.3 ± 1.03-1.2 ± 6.72
Week 116-5.1 ± 20.890.4 ± 9.00
Week 132-3.6 ± 20.980.5 ± 10.75
Week 148-4.1 ± 8.75-1.4 ± 4.23
Week 160-9.9 ± 4.31-10.0 ± 11.64
SecondaryDouble Masked Period: PhNR/B-wave Amplitude Ratio

Double Masked Period: Change from baseline in PhNR/b-wave amplitude ratio by Visit. Photopic negative response electroretinography (PhNR assesses retinal cell function. A decrease in PhNR amplitude means worse outcome.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Reported as:
Mean · ratio
Double Masked Period: PhNR/B-wave Amplitude Ratio
ratioVehicle EyesElamipretide Eyes
Week 4-0.102 ± 0.2225-0.033 ± 0.2793
Week 8-0.036 ± 0.3101-0.033 ± 0.3385
Week 12-0.113 ± 0.24150.019 ± 0.1721
Week 16-0.059 ± 0.1179-0.070 ± 0.2285
Week 20-0.018 ± 0.2005-0.066 ± 0.2365
Week 24-0.052 ± 0.20800.014 ± 0.2131
Week 28-0.044 ± 0.2281-0.024 ± 0.1634
Week 32-0.033 ± 0.2414-0.031 ± 0.1513
Week 36-0.104 ± 0.2479-0.013 ± 0.1795
Week 40-0.007 ± 0.2190-0.046 ± 0.1202
Week 44-0.138 ± 0.31940.013 ± 0.2206
Week 48-0.020 ± 0.2366-0.059 ± 0.1533
Week 52-0.044 ± 0.2428-0.029 ± 0.1299
Week 56 (Follow up)0.009 ± 0.2670-0.063 ± 0.1149
SecondaryOpen Label Extension Period: Change From Baseline by Visit PhNR/b Wave Amplitude Ratio

Open Label Extension Period: Change from baseline by visit PhNR/b Wave Amplitude Ratio by visit. A reduced amplitude ratio equals worse outcome.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · Ratio
Open Label Extension Period: Change From Baseline by Visit PhNR/b Wave Amplitude Ratio
RatioVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 68-0.097 ± 0.2453-0.002 ± 0.1722
Week 84-0.021 ± 0.2678-0.041 ± 0.1207
Week 1000.012 ± 0.1523-0.003 ± 0.0796
Week 1040.019 ± 0.0066-0.048 ± 0.0667
Week 116-0.034 ± 0.21120.000 ± 0.0971
Week 132-0.055 ± 0.19570.032 ± 0.2010
Week 148-0.035 ± 0.0717-0.046 ± 0.0982
Week 160-0.155 ± 0.1075-0.212 ± 0.2211
SecondaryDouble Masked Period: Change From Baseline by Visit PhNR Peak to Trough Adjusted for A-wave Amplitude

Double Masked Period: Change from baseline by visit in PhNR Peak to Trough Adjusted for a-wave Amplitude by Visit. Calculated as (b-wave amplitude - PhNR amplitude)/a-wave amplitude. A reduced amplitude ratio equals worse outcome.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Reported as:
Mean · Ratio
Double Masked Period: Change From Baseline by Visit PhNR Peak to Trough Adjusted for A-wave Amplitude
RatioVehicle EyesElamipretide Eyes
Week 40.18 ± 0.392-0.21 ± 1.100
Week 8-0.03 ± 0.6551.08 ± 4.628
Week 120.08 ± 0.8270.00 ± 0.962
Week 16-0.53 ± 1.260-0.01 ± 0.862
Week 20-0.32 ± 0.9920.10 ± 1.022
Week 24-0.35 ± 0.856-0.29 ± 0.746
Week 28-0.35 ± 0.819-0.21 ± 1.358
Week 32-0.24 ± 0.820-0.15 ± 0.606
Week 36-0.05 ± 0.687-0.70 ± 1.162
Week 400.63 ± 0.5460.02 ± 1.123
Week 44-0.68 ± 0.438-0.66 ± 1.016
Week 48-0.61 ± 0.811-0.31 ± 0.769
Week 52-0.61 ± 0.291-0.37 ± 0.403
Week 56 (Follow up)-1.22 ± 0.114-0.87 ± 0.274
SecondaryOpen Label Extension Period: Change From Baseline by Visit PhNR Peak to Trough Adjusted for A-wave Amplitude

Open Label Extension Period: Change from baseline by visit in PhNR Peak to Trough Adjusted for a-wave Amplitude by Visit. \[Calculated by b-wave amplitude - PhNR amplitude)/a-wave amplitude.\] Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes. A reduced amplitude ratio equals worse outcome.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · Ratio
Open Label Extension Period: Change From Baseline by Visit PhNR Peak to Trough Adjusted for A-wave Amplitude
RatioVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 68-0.31 ± 1.006-0.70 ± 0.859
Week 840.25 ± 1.700-0.09 ± 1.050
Week 100-0.30 ± 0.591-0.13 ± 0.407
Week 104-0.10 ± 0.454-0.09 ± 0.103
Week 116-0.64 ± 1.189-0.46 ± 0.673
Week 132-0.77 ± 0.831-0.38 ± 0.329
Week 148-0.91 ± 0.609-0.16 ± 0.437
Week 160-0.46 ± 0.457-0.92 ± 1.027
SecondaryDouble Masked Period: PhNR Peak to Trough Amplitude (Unadjusted) From Baseline

Double Masked Period: Change from baseline in PhNR Peak to Trough Amplitude (Unadjusted) by Visit. Calculated as b-wave amplitude - PhNR amplitude. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in amplitude is associated with worse outcomes.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Reported as:
Mean · µV
Double Masked Period: PhNR Peak to Trough Amplitude (Unadjusted) From Baseline
µVVehicle EyesElamipretide Eyes
Week 4-2.72 ± 24.750-4.80 ± 31.025
Week 80.08 ± 18.496-0.08 ± 31.421
Week 1215.16 ± 38.01615.38 ± 33.898
Week 161.70 ± 32.0160.52 ± 25.629
Week 20-2.62 ± 20.398-3.29 ± 21.498
Week 24-4.57 ± 25.171-0.54 ± 30.470
Week 286.38 ± 26.095-10.18 ± 19.504
Week 32-1.42 ± 28.2944.86 ± 26.750
Week 3610.94 ± 48.0515.57 ± 26.427
Week 402.22 ± 43.149-3.74 ± 27.206
Week 4411.74 ± 46.933-3.46 ± 26.042
Week 48-4.12 ± 34.581-6.86 ± 28.849
Week 522.73 ± 19.124-2.15 ± 22.109
Week 56 (Follow up)-16.78 ± 19.472-11.80 ± 49.865
SecondaryOpen Label Extension Period: PhNR Peak to Trough Amplitude (Unadjusted)

Open Label Extension Period: Change from baseline in PhNR Peak to Trough Amplitude (Unadjusted) by Visit. b-wave amplitude - PhNR amplitude. Photopic negative response electroretinography (PhNR-ERG) assesses retinal cell function. A decrease in the amplitude of the a-wave is associated with worse outcomes.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · µV
Open Label Extension Period: PhNR Peak to Trough Amplitude (Unadjusted)
µVVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 68-8.36 ± 36.178-7.92 ± 21.402
Week 84-3.50 ± 13.206-10.90 ± 22.928
Week 100-32.02 ± 23.994-21.64 ± 21.432
Week 104-21.01 ± 4.193-13.01 ± 11.340
Week 11622.26 ± 42.3524.52 ± 22.231
Week 132-13.56 ± 27.012-1.85 ± 15.341
Week 148-8.99 ± 35.662-5.84 ± 19.242
Week 160-7.87 ± 11.415-28.17 ± 31.249
SecondaryDouble Masked: VFQ-39 Composite

Double Masked: Change from baseline in Visual Function Questionnaire (VFQ-39) Composite score by visit. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Composite
score on a scaleSingle EyeBilateral Eye
Week 526.1 ± 5.635.7 ± 8.07
Week 56 (Follow-up Visit)7.8 ± 7.02—
SecondaryOpen Label Extension Period: VFQ-39 Composite Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Composite score.National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 Composite Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 Composite Score5.6 ± 11.3013.9 ± 8.66
SecondaryOpen Label Extension Period: VFQ-39 General Health Score

Change from baseline in Visual Function Questionnaire (VFQ-39) General Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 General Health Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 General Health Score-6.8 ± 10.586.7 ± 11.55
SecondaryDouble Masked: VFQ-39 General Vision Score

Change from baseline in VFQ-39 General Vision Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculate

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 General Vision Score
score on a scaleSingle EyeBilateral Eye
Week 528.1 ± 8.841.3 ± 11.09
Week 56 (Follow-up Visit)3.3 ± 7.64—
SecondaryOpen Label Extension Period: VFQ-39 General Vision Score

Change from baseline in VFQ-39 General Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculate

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 General Vision Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 General Vision Score9.3 ± 13.366.7 ± 11.55
SecondaryDouble Masked: VFQ-39 Ocular Pain Score

Change from baseline in VFQ-39 Ocular Pain score. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Ocular Pain Score
score on a scaleSingle EyeBilateral Eye
Week 521.6 ± 12.393.1 ± 6.25
Week 56 (Follow-up Visit)12.5 ± 12.50—
SecondaryOpen Label Extension Period: VFQ-39 Ocular Pain Score

Change from baseline in VFQ-39 Ocular Pain score by visit. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 Ocular Pain Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 Ocular Pain Score-16.1 ± 20.04-4.2 ± 7.22
SecondaryDouble Masked: VFQ-39 Near Activities Score

Change from Baseline in VFQ-39 Near Activities Score from Baseline. National Eye Institute VFQ-39 measures health-related quality of life in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, peripheral vision, and composite score. For each domain: the lowest and highest possible scores are 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Near Activities Score
score on a scaleSingle EyeBilateral Eye
Week 523.6 ± 7.539.2 ± 9.41
Week 56 (Follow-up Visit)11.1 ± 9.62—
SecondaryOpen Label Extension Period: VFQ-39 Near Activities

Change from Baseline in Visual Function Questionnaire (VFQ-39) Near Activities score.. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; score ranges from 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 Near Activities
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 Near Activities8.5 ± 11.0316.7 ± 16.67
SecondaryDouble Masked Period: Mean Retinal Nerve Fiber (RNFL) Layer Thickness

Change from baseline in retinal nerve fiber layer thickness by spectral domain optical coherence tomography (SD-OCT). RNFL measures the loss of retinal ganglion cell axons. RNFL thickness decreases as disease progresses. A positive number, or, absence of change from baseline reflects a good clinical outcome, a negative number reflects loss of thickness, or a bad outcome.

Time frame:
Assessed at Baseline and Week 52 (end-of-treatment visit)
Reported as:
Mean · µm
Double Masked Period: Mean Retinal Nerve Fiber (RNFL) Layer Thickness
µmVehicle EyesElamipretide Eyes
Double Masked Period: Mean Retinal Nerve Fiber (RNFL) Layer Thickness-3.8 ± 7.52-2.6 ± 4.76
SecondaryOpen Label Extension Period: Retinal Nerve Fiber Layer Thickness

Open Label Extension Period: Change from baseline in Retinal Nerve Fiber Layer Thickness by SD-OCT by visit. Change from baseline in retinal nerve fiber layer thickness by spectral domain optical coherence tomography (SD-OCT). RNFL measures the loss of retinal ganglion cell axons. RNFL thickness decreases as disease progresses. A positive number, or, absence of change from baseline reflects a good clinical outcome, a negative number reflects loss of thickness, or a bad outcome.

Time frame:
Assessed at Baseline, Week 148
Reported as:
Mean · µm
Open Label Extension Period: Retinal Nerve Fiber Layer Thickness
µmVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Open Label Extension Period: Retinal Nerve Fiber Layer Thickness-1.01.4 ± 2.70
SecondaryDouble Masked Period: Visual Field Mean Deviation as Measured by Humphrey Automated Visual Field Testing Stimulus III

Change from Baseline in visual field Mean Deviation(MD) as measured by Humphrey automated visual field testing stimulus III by visit. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. Mean deviation (MD) is the mean deviation in the patient's results compared to those expected from the age-matched normative database. Lower/More negative scores mean worse outcome, higher/more positive score means better outcome.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit), except for Day 5 visit.
Reported as:
Mean · dB
Double Masked Period: Visual Field Mean Deviation as Measured by Humphrey Automated Visual Field Testing Stimulus III
dBVehicle EyesElamipretide Eyes
Week 41.1 ± 3.622.1 ± 3.94
Week 80.5 ± 3.881.6 ± 3.82
Week 120.4 ± 3.850.9 ± 3.42
Week 160.3 ± 1.871.9 ± 2.62
Week 20-0.4 ± 5.312.1 ± 4.23
Week 242.0 ± 3.331.1 ± 2.74
Week 281.7 ± 4.401.3 ± 4.86
Week 322.9 ± 4.271.4 ± 4.38
Week 362.6 ± 4.752.2 ± 3.55
Week 402.8 ± 5.982.2 ± 3.55
Week 441.8 ± 6.032.8 ± 5.10
Week 481.5 ± 3.661.4 ± 3.92
Week 520.9 ± 4.182.2 ± 3.30
Week 56 (Follow up)3.7 ± 5.671.6 ± 3.53
SecondaryOpen Label Extension Period: Visual Field Mean Deviation (dB) Measured by Humphrey From Baseline

Change from Baseline in visual field Mean Deviation(MD) as measured by Humphrey automated visual field testing stimulus III by visit. The Humphrey visual field test measures the entire area of peripheral vision that can be seen while the eye is focused on a central point. Mean deviation (MD) is the mean deviation in the patient's results compared to those expected from the age-matched normative database. Lower/More negative scores mean worse outcome, higher/more positive score means better outcome.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · dB
Open Label Extension Period: Visual Field Mean Deviation (dB) Measured by Humphrey From Baseline
dBVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 683.3 ± 5.594.0 ± 6.66
Week 845.1 ± 6.664.4 ± 6.53
Week 1003.1 ± 6.855.5 ± 8.04
Week 1040.9 ± 0.972.9 ± 0.99
Week 1164.4 ± 5.484.7 ± 6.21
Week 1324.7 ± 8.434.0 ± 6.62
Week 1485.5 ± 8.165.6 ± 9.51
Week 1606.3 ± 13.6711.5 ± 16.98
SecondaryDouble Masked Period: Color Discrimination - Number of Plates

Double Masked Period: Change from Baseline in Color Discrimination - Number of Plates from Baseline by Visit by Ishihara Test. Score range: 0-38. Higher number equals better color discrimination equals better outcome. Lower number equals worse color discrimination equals worse outcome.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit)
Reported as:
Mean · Plates
Double Masked Period: Color Discrimination - Number of Plates
PlatesVehicle EyesElamipretide Eyes
Day 50.0 ± 0.000.1 ± 0.57
Week 40.0 ± 0.000.1 ± 0.50
Week 80.1 ± 0.350.3 ± 0.58
Week 120.3 ± 0.710.2 ± 0.75
Week 160.0 ± 0.000.4 ± 0.89
Week 200.5 ± 0.930.3 ± 0.60
Week 240.3 ± 0.710.5 ± 0.97
Week 280.9 ± 1.360.8 ± 1.39
Week 320.8 ± 1.160.7 ± 1.30
Week 360.8 ± 1.160.8 ± 1.05
Week 400.5 ± 0.760.6 ± 0.81
Week 441.0 ± 1.070.9 ± 1.31
Week 481.3 ± 1.391.1 ± 1.34
Week 521.6 ± 1.601.1 ± 1.09
Week 56 (Follow up)1.7 ± 2.891.0 ± 1.00
SecondaryOpen Label Extension Period: Change From Baseline in Color Discrimination - Number of Plates by Visit

Open Label Extension Period: Change from Baseline in Color Discrimination - Number of Plates from Baseline by Visit by Ishihara Test. Score range: 0-38. Higher number equals better color discrimination equals better outcome. Lower number equals worse color discrimination equals worse outcome.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · plates
Open Label Extension Period: Change From Baseline in Color Discrimination - Number of Plates by Visit
platesVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 681.3 ± 1.281.4 ± 1.36
Week 841.9 ± 1.961.6 ± 1.75
Week 1002.8 ± 3.652.0 ± 2.54
Week 1040.0 ± 0.000.5 ± 0.71
Week 1162.4 ± 2.701.2 ± 1.92
Week 1322.0 ± 1.831.6 ± 1.33
Week 1481.0 ± 0.820.9 ± 0.35
Week 1602.0 ± 2.001.3 ± 1.53
SecondaryDouble Masked Period: Change From Baseline in Contrast Sensitivity by Pelli-Robson Contrast Sensitivity Chart by Visit

Letters are arranged on a 60 x 85 cm chart in sets of triplets which contain the same contrast, decreasing in log10 contrast from top to bottom and left to right as participant progresses from one triplet to the other. Each group of three letters is decreased in contrast by a factor 0.71 (1/√2) (log contrast 0.15) of the proceeding set. Participant reads letters, starting with highest contrast, until unable to read letters in a single group. Score is based on the contrast of the last group read correctly.The size of the letters on the chart subtend 0.5 degrees at 3m, The test is scored in LogCS units, where each set of triplets advances in steps of 0.15 log units ranging from LogCS of 0.00 (approx. 100% contrast) to LogCS 2.25 (approx. 0.56% contrast). Change from baseline: the more negative the number means poor outcome, the more positive the number means better outcome.

Time frame:
Assessed at each visit from Baseline to Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked Period: Change From Baseline in Contrast Sensitivity by Pelli-Robson Contrast Sensitivity Chart by Visit
score on a scaleVehicle EyesElamipretide Eyes
Day 50.075 ± 0.0802-0.019 ± 0.1078
Week 40.038 ± 0.0694-0.028 ± 0.1366
Week 80.075 ± 0.11340.047 ± 0.1420
Week 120.056 ± 0.11160.000 ± 0.1342
Week 160.075 ± 0.1134-0.009 ± 0.1020
Week 200.094 ± 0.1116-0.009 ± 0.1020
Week 240.075 ± 0.11340.028 ± 0.1663
Week 280.113 ± 0.1747-0.009 ± 0.1393
Week 320.113 ± 0.15530.028 ± 0.1663
Week 360.150 ± 0.16040.056 ± 0.1806
Week 400.206 ± 0.17820.075 ± 0.1975
Week 440.225 ± 0.22680.066 ± 0.2625
Week 480.188 ± 0.22320.084 ± 0.1446
Week 520.225 ± 0.21210.075 ± 0.2258
Week 56 (Follow up)0.100 ± 0.08660.050 ± 0.0866
SecondaryOpen Label Extension Period: Change From Baseline in Contrast Sensitivity by Visit

Letters are arranged on a 60 x 85 cm chart in sets of triplets which contain the same contrast, decreasing in log10 contrast from top to bottom and left to right as participant progresses from one triplet to the other. Each group of three letters is decreased in contrast by a factor 0.71 (1/√2) (log contrast 0.15) of the proceeding set. Participant reads letters, starting with highest contrast, until unable to read letters in a single group. Score is based on the contrast of the last group read correctly. The size of the letters on the chart subtend 0.5 degrees at 3m, The test is scored in LogCS units, where each set of triplets advances in steps of 0.15 log units ranging from LogCS of 0.00 (approx. 100% contrast) to LogCS 2.25 (approx. 0.56% contrast). Change from baseline: the more negative the number means poor outcome, the more positive the number means better outcome.

Time frame:
Assessed at each visit from Baseline from Week 68 to Week 160
Reported as:
Mean · score on a scale
Open Label Extension Period: Change From Baseline in Contrast Sensitivity by Visit
score on a scaleVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 680.225 ± 0.21210.084 ± 0.1972
Week 840.300 ± 0.19640.122 ± 0.1991
Week 1000.281 ± 0.20340.118 ± 0.2893
Week 1040.075 ± 0.10610.075 ± 0.1061
Week 1160.300 ± 0.30000.196 ± 0.2626
Week 1320.214 ± 0.19090.127 ± 0.2796
Week 1480.225 ± 0.25980.113 ± 0.1553
Week 1600.150 ± 0.25980.100 ± 0.0866
SecondaryDouble Masked Change From Baseline in Retinal Ganglion Cell Layer Thickness

Change from baseline in Retinal Ganglion Cell Layer Thickness by SD-OCT From Baseline by Visit

Time frame:
Assessed at Baseline and Week 52 (end-of-treatment visit)
Reported as:
Mean · µm
Double Masked Change From Baseline in Retinal Ganglion Cell Layer Thickness
µmVehicle EyesElamipretide Eyes
Double Masked Change From Baseline in Retinal Ganglion Cell Layer Thickness-1.5 ± 4.00-3.6 ± 13.49
SecondaryOpen Label Extension Period: Change From Baseline in Retinal Ganglion Cell Layer Thickness

Open Label Extension Period: Change from baseline in Retinal Ganglion Cell Layer Thickness by SD-OCT by SD-OCT by visit

Time frame:
Assessed at Baseline, Week 148,
Reported as:
Mean · µm
Open Label Extension Period: Change From Baseline in Retinal Ganglion Cell Layer Thickness
µmVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Open Label Extension Period: Change From Baseline in Retinal Ganglion Cell Layer Thickness-1.03.4 ± 6.07
SecondaryDouble Masked: VFQ-39 Distance Activities Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Distance Activities score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Distance Activities Score
score on a scaleSingle EyeBilateral Eye
Week 529.4 ± 12.940.0 ± 14.03
Week 56 (Follow-up Visit)54.2 ± 14.43—
SecondaryOpen Label Extension Period: VFQ-39 Distance Activities Score

Change in Visual Function Questionnaire (VFQ-39) Distance Activities Score.National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 Distance Activities Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 Distance Activities Score12.5 ± 20.5613.9 ± 6.36
SecondaryOpen Label Extension Period: VFQ-39 Social Functioning Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Social Functioning Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 Social Functioning Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 Social Functioning Score8.3 ± 11.785.6 ± 17.35
SecondaryDouble Masked: VFQ-39 Social Functioning Score.

Change from baseline in Visual Function Questionnaire (VFQ-39) Social Functioning score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Social Functioning Score.
score on a scaleSingle EyeBilateral Eye
Week 526.3 ± 10.680.0 ± 19.25
Week 56 (Follow-up Visit)16.7 ± 8.34—
SecondaryDouble Masked: VFQ-39 Mental Health Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Mental Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Mental Health Score
score on a scaleSingle EyeBilateral Eye
Week 5212.0 ± 9.1619.7 ± 32.47
Week 56 (Follow-up Visit)13.3 ± 25.17—
SecondaryOpen Label Extension Period: VFQ-39 Mental Health Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Mental Health Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 Mental Health Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 Mental Health Score16.4 ± 22.3129.2 ± 29.83
SecondaryDouble Masked: VFQ-39 Role Difficulties Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Role Difficulties score National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Role Difficulties Score
score on a scaleSingle EyeBilateral Eye
Week 524.7 ± 10.4314.1 ± 9.38
Week 56 (Follow-up Visit)10.4 ± 13.01—
SecondaryOpen Label Extension Period: VFQ-39 Role Difficulties Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Role Difficulties Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 Role Difficulties Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 Role Difficulties Score8.0 ± 12.8737.5 ± 16.54
SecondaryOpen Label Extension Period:VFQ-39 Dependency Score

Change from baseline in Visual Function Questionnaire (VFQ-39 ) Dependency Score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period:VFQ-39 Dependency Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period:VFQ-39 Dependency Score16.1 ± 13.9127.1 ± 3.61
SecondaryDouble Masked: VFQ-39 Dependency Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Dependency score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Dependency Score
score on a scaleSingle EyeBilateral Eye
Week 529.4 ± 22.10-2.6 ± 24.85
Week 56 (Follow-up Visit)-8.3 ± 23.66—
SecondaryDouble Masked: VFQ-39 Color Vision Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Color Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Color Vision Score
score on a scaleSingle EyeBilateral Eye
Week 526.3 ± 17.686.3 ± 12.50
Week 56 (Follow-up Visit)0.0 ± 25.00—
SecondaryOpen Label Extension Period: VFQ-39 Color Vision Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Color Vision score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: VFQ-39 Color Vision Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: VFQ-39 Color Vision Score-7.1 ± 18.908.3 ± 14.43
SecondaryDouble Masked: VFQ-39 Peripheral Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Peripheral Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 Peripheral Score
score on a scaleSingle EyeBilateral Eye
Week 520.0 ± 13.366.3 ± 12.50
Week 56 (Follow-up Visit)66.7 ± 14.43—
SecondaryOpen Label Extension Period: Visual Function Questionnaire (VFQ-39) Peripheral Score

Change from baseline in Visual Function Questionnaire (VFQ-39) Peripheral Score . National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 160 (End of OLE Period)
Reported as:
Mean · score on a scale
Open Label Extension Period: Visual Function Questionnaire (VFQ-39) Peripheral Score
score on a scaleSingle Eye in DM PeriodBilateral Eye in DM Period
Open Label Extension Period: Visual Function Questionnaire (VFQ-39) Peripheral Score0.0 ± 32.270.0 ± 25.00
SecondaryDouble Masked Period: Change in Intraocular Pressure (IOP)

Double Masked Period: Change in intraocular Pressure (IOP) in mmHg from Baseline by Visit

Time frame:
Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Reported as:
Mean · mmHg
Double Masked Period: Change in Intraocular Pressure (IOP)
mmHgDouble Masked Group Vehicle EyesDouble Masked Group Elamipretide Eyes
Day 5-0.3 ± 1.67-0.2 ± 1.87
Week 40.0 ± 3.16-0.4 ± 2.16
Week 8-0.4 ± 1.77-0.5 ± 1.83
Week 120.5 ± 2.39-0.5 ± 2.53
Week 160.4 ± 1.510.6 ± 3.14
Week 200.4 ± 1.85-0.3 ± 1.66
Week 24-0.1 ± 3.31-0.4 ± 2.99
Week 280.3 ± 1.830.3 ± 1.88
Week 320.0 ± 2.62-0.3 ± 1.92
Week 36-1.1 ± 1.55-1.3 ± 1.96
Week 400.3 ± 2.25-0.6 ± 1.75
Week 44-0.4 ± 2.00-0.3 ± 1.85
Week 480.5 ± 3.660.8 ± 2.79
Week 52-1.0 ± 1.20-0.5 ± 2.66
Week 56 (follow up Visit)-1.0 ± 1.20-0.5 ± 2.66
SecondaryOpen Label Extension Period: Intraocular Pressure (IOP)

Change from baseline in Intraocular Pressure (IOP) in mmHg by Visit.

Time frame:
Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Reported as:
Mean · mmHg
Open Label Extension Period: Intraocular Pressure (IOP)
mmHgVehicle to Elamipretide EyesElamipretide to Elamipretide Eyes
Week 68-0.4 ± 1.600.8 ± 2.49
Week 841.4 ± 3.290.4 ± 2.37
Week 100-0.9 ± 2.03-0.2 ± 2.22
Week 1041.5 ± 2.12-1.0 ± 1.41
Week 1160.1 ± 3.18-0.5 ± 2.63
Week 1320.1 ± 1.350.1 ± 1.80
Week 1481.3 ± 2.06-0.1 ± 2.36
Week 1600.7 ± 0.58-1.7 ± 1.53
SecondaryOLE: Slit Lamp Examination (SLE)-Vehicle Eye

Open Label Extension: Shift in Slit Lamp Examination from Baseline by Visit: number of eyes that changed from normal or abnormal not clinically significant, to abnormal clinically significant for Vehicle Eyes

Time frame:
Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Reported as:
Number · eyes
OLE: Slit Lamp Examination (SLE)-Vehicle Eye
eyesNormal to Abnormal CSShift From Abnormal NCS to Abnormal CS
Lids Eye Week 6800
Lids Week 8400
Lids Week 10000
Lids Week 10400
Lids Week 11600
Lids Week 13200
Lids Week 14800
Lids Week 16000
Conjunctiva 6800
Conjunctiva 8400
Conjunctiva 10000
Conjunctiva 10400
Conjunctiva 11600
Conjunctiva 13200
Conjunctiva 14800
Conjunctiva 16000
Cornea Week 6800
Cornea Week 8410
Cornea Week 10010
Cornea Week 10400
Cornea Week 11600
Cornea Week 13200
Cornea Week 14800
Cornea Week 16000
Anterior Chamber 6800
Anterior Chamber 8400
Anterior Chamber 10000
Anterior Chamber 10400
Anterior Chamber 11600
Anterior Chamber 13200
Anterior Chamber 14800
Anterior Chamber 16000
Iris Week 6800
Iris Week 8400
Iris Week 10000
Iris Week 10400
Iris Week 11600
Iris Week 13200
Iris Week 14800
Iris Week 16000
Lens Week 6800
Lens Week 8400
Lens Week 10000
Lens Week 10400
Lens Week 11610
Lens Week 13200
Lens Week 14800
Lens Week 16000
Vitreous Week 6800
Vitreous Week 8400
Vitreous Week 10000
Vitreous Week 10400
Vitreous Week 11600
Vitreous Week 13200
Vitreous Week 14800
Vitreous Week 16000
Retina Week 6800
Retina Week 8400
Retina Week 10000
Retina Week 10400
Retina Week 11600
Retina Week 13200
Retina Week 14800
Retina Week 16000
Optic nerve Week 6800
Optic nerve Week 8400
Optic nerve Week 10000
Optic nerve Week 10400
Optic nerve Week 11600
Optic nerve Week13200
Optic nerve Week 14800
Optic nerve Week 16000
Macula Week 6800
Macula Week 8400
Macula Week 10000
Macula Week 10400
Macula Week 11600
Macula Week 13200
Macula Week 14800
Macula Week 16000
Choroid Week 6800
Choroid Week 8400
Choroid Week 10000
Choroid Week 10400
Choroid Week 11600
Choroid Week 13200
Choroid Week 14800
Choroid Week 16000
Periphery Week 6800
Periphery Week 8400
Periphery Week 10000
Periphery Week 10400
Periphery Week 11600
Periphery Week 13200
Periphery Week 14800
Periphery 16000
SecondaryOLE: Slit Lamp Examination (SLE)-Elamipretide Eye

Open Label Extension: Shift in Slit Lamp Examination from Baseline by Visit: number of eyes that changed from normal or abnormal not clinically significant, to abnormal clinically significant for Elamipretide Eyes

Time frame:
Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Reported as:
Number · eyes
OLE: Slit Lamp Examination (SLE)-Elamipretide Eye
eyesNormal to Abnormal CSShift From Abnormal NCS to Abnormal CS
Lids Eye Week 6800
Lids Week 8400
Lids Week 10000
Lids Week 10400
Lids Week 11600
Lids Week 13200
Lids Week 14800
Lids Week 16000
Conjunctiva 6800
Conjunctiva 8400
Conjunctiva 10000
Conjunctiva 10400
Conjunctiva 11600
Conjunctiva 13200
Conjunctiva 14800
Conjunctiva 16000
Cornea Week 6800
Cornea Week 8400
Cornea Week 10000
Cornea Week 10400
Cornea Week 11600
Cornea Week 13200
Cornea Week 14800
Cornea Week 16000
Anterior Chamber 6800
Anterior Chamber 8400
Anterior Chamber 10000
Anterior Chamber 10400
Anterior Chamber 11600
Anterior Chamber 13200
Anterior Chamber 14800
Anterior Chamber 16000
Iris Week 6800
Iris Week 8400
Iris Week 10000
Iris Week 10400
Iris Week 11600
Iris Week 13200
Iris Week 14800
Iris Week 16000
Lens Week 6800
Lens Week 8400
Lens Week 10000
Lens Week 10400
Lens Week 11610
Lens Week 13200
Lens Week 14800
Lens Week 16000
Vitreous Week 6800
Vitreous Week 8400
Vitreous Week 10000
Vitreous Week 10400
Vitreous Week 11600
Vitreous Week 13200
Vitreous Week 14800
Vitreous Week 16000
Retina Week 6800
Retina Week 8400
Retina Week 10000
Retina Week 10400
Retina Week 11600
Retina Week 13200
Retina Week 14800
Retina Week 16000
Optic nerve Week 6800
Optic nerve Week 8400
Optic nerve Week 10000
Optic nerve Week 10400
Optic nerve Week 11600
Optic nerve Week 13200
Optic nerve Week 14800
Optic nerve Week 16000
Macula Week 6800
Macula Week 8400
Macula Week 10000
Macula Week 10400
Macula Week 11600
Macula Week 13200
Macula Week 14800
Macula Week 16000
Choroid Week 6800
Choroid Week 8400
Choroid Week 10000
Choroid Week 10400
Choroid Week 11600
Choroid Week 13200
Choroid Week 14800
Choroid Week 16000
Periphery Week 6800
Periphery Week 8400
Periphery Week 10000
Periphery Week 10400
Periphery Week 11600
Periphery Week 13200
Periphery Week 14800
Periphery 16000
SecondaryDouble Masked: Slit Lamp Changes From Baseline: Vehicle Eye and Elamipretide Eye

Incidence of Change from normal or Abnormal, clinically insignificant to normal clinically significant

Time frame:
Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Reported as:
Number · eyes
Double Masked: Slit Lamp Changes From Baseline: Vehicle Eye and Elamipretide Eye
eyesDouble Masked Group Vehicle EyesDouble Masked Group Elamipretide Eyes
Conjunctiva Week 4 Normal to Abnormal Clinically significant10
Conjunctiva: Week 8 Normal to Abnormal Clinically significant10
Conjunctiva: Week 16 Normal to Abnormal Clinically significant11
Conjunctiva: Week 28 Normal to Abnormal Clinically significant11
Conjunctiva: Week 44 Normal to Abnormal Clinically significant11
Lids: Week 28 Normal to Abnormal Clinically significant01
Cornea: Week 32 Normal to Abnormal Clinically significant02
Cornea: Week 44 Normal to Abnormal Clinically significant11
SecondaryDouble Masked: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes

Double Masked: Dilated Fundus Changes from Baseline: Vehicle Eye and Elamipretide Eyes Incidence of Change from normal or Abnormal-clinically insignificant, to normal clinically significant

Time frame:
Assessed at each visit: Baseline, Day 5 Visit, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 (End of treatment visit) and Week 56 (Follow up visit)
Reported as:
Number · eyes
Double Masked: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes
eyesVehicle EyesElamipretide Eyes
Double Masked: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes00
SecondaryOpen Label Extension Period: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes

Incidence of Change from normal or Abnormal-clinically insignificant, to normal clinically significant

Time frame:
Assessed at Baseline, Week 68, 84, 100, 116, 132, 148, 152, Week 160/ (End of treatment visit)
Reported as:
Number · eyes
Open Label Extension Period: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes
eyesVehicle EyesElamipretide Eyes
Open Label Extension Period: Dilated Fundus Changes From Baseline: Vehicle Eye and Elamipretide Eyes00
SecondaryDouble Masked: VFQ-39 General Health Score

Change from baseline in Visual Function Questionnaire (VFQ-39) General Health score. National Eye Institute VFQ-39 score measures health-related quality of life of subjects with visual impairment, in 12 domains: general vision, ocular pain, near activities, distance activities, vision-specific social functioning, vision-specific mental health, vision-specific role difficulties, vision-specific dependency, driving, color vision, and peripheral vision and 1 composite score. Each domain is converted to a 0 to 100 scale; the lowest and highest possible scores are set at 0 and 100 points, respectively. Higher score means higher functioning. Scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score. For the composite score, the vision-targeted sub-scale scores are averaged, excluding the general health questions. Domain scores from each cohort are averaged and the change from baseline per domain is calculated.

Time frame:
Assessed at Baseline, Week 52 (end-of-treatment visit) and Week 56 (follow-up visit)
Reported as:
Mean · score on a scale
Double Masked: VFQ-39 General Health Score
score on a scaleSingle EyeBilateral Eye
Week 52-3.8 ± 10.09-0.6 ± 19.72
Week 56 (Follow-up Visit)-5.8 ± 6.29—

Adverse events

Collected over Up to 112 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
One Eye DM Period0/8 (0%)0/8 (0%)6/8 (75%)
Both Eyes DM Period0/4 (0%)0/4 (0%)3/4 (75%)
(One Eye DM Period) OLE0/8 (0%)0/8 (0%)7/8 (87.5%)
(Both Eyes DM) OLE Period0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 33
Most frequent other events
EventOne Eye DM PeriodBoth Eyes DM Period(One Eye DM Period) OLE(Both Eyes DM) OLE Period
Blood glucose decreasedInvestigations0/81/43/80/4
HypersensitivityImmune system disorders1/81/40/80/4
NasopharyngitisInfections and infestations2/81/42/81/4
SinusitisInfections and infestations2/80/40/81/4
InfluenzaInfections and infestations1/80/42/81/4
Muscle strainInjury, poisoning and procedural complications0/81/40/80/4
DysgeusiaNervous system disorders2/81/40/80/4
NephrolithiasisRenal and urinary disorders0/81/40/80/4
CoughRespiratory, thoracic and mediastinal disorders2/80/40/80/4
PyrexiaGeneral disorders0/80/40/81/4

Baseline characteristics

All participants for whom age (continuous) was measured.

Age, Continuous
Age, Continuous(years)Group 2Group 3Total
Mean35.4 ± 14.4730.0 ± 4.8333.6 ± 12.11
Sex: Female, Male
Sex: Female, Male(Participants)Group 2Group 3Total
Female112
Male7310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 2Group 3Total
Hispanic or Latino123
Not Hispanic or Latino628
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 2Group 3Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White707
More than one race044
Unknown or Not Reported101
Elamipretide eye
Elamipretide eye(Participants)Group 2Group 3Total
right eye only404
left eye only404
both eyes044
BMI
BMI(kg/m^2)Group 2Group 3Total
Mean25.70 ± 3.93729.43 ± 2.08126.94 ± 3.796
08

Study locations

1 site
  • Doheny Eye Center
    Pasadena, California 91105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Sep 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2021, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2016
First posted
Feb 26, 2016
Start
Mar 2016
Primary completionActual
Sep 2019
CompletionActual
Dec 2019
Results first posted
Oct 12, 2021
Last update
Nov 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02693119
Responsible party
Sponsor
First posted
Feb 26, 2016
Start date
Mar 2016
Primary completion
Sep 2019
Completion
Dec 2019
Results posted
Oct 12, 2021
Last update
Nov 30, 2021

Study contacts

Alfredo Sadun, MD, PhD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion